This session will review the epidemiology and basic pharmacokinetics of psychedelic drugs and how their unique properties may make them suitable choices for treating substance use disorders, anxiety and depression. Current clinical and neuroimaging research will be critically reviewed in addition to an exploration of the role of psychedelics in international clinics. We will hold a discussion concerning if and how the counseling profession can help guide safe, ethical development of these treatments.
The presentation will approach the topic of using SPDs in counseling first and foremost from a neurophysiological approach as an accurate and current scientific understanding of these drugs is crucial to understanding why they may be effective. Current literature concerning SPDs’ clinical use will then be critically reviewed with respect to study design & implementation. After establishing this scientific groundwork and providing an overview of SPD’s clinical use, attendees will have a discussion surrounding the ethics of SPD use in counseling.
Attendees will learn about how serotonergic psychedelic drugs (SPDs) such as ayahuasca, ibogaine, psilocybin, and LSD are classified and how they have been used throughout history both in Western and indigenous cultures.
Attendees will learn about neurophysiological pathways of SPDs and how their effects may work to treat mental illness and substance use disorders.
Attendees will review research on the clinical use of SPDs, how they are being used outside of the United States in treatment clinics, and clinician’s role in their safe & ethical use.
Trauma and Addictions Specialist,
Mental Illness Recovery Center Inc.